Hypofractionated High-Dose Irradiation with Positron Emission Tomography Data for the Treatment of Glioblastoma Multiforme
Figure 3
Overall survival (a) and progression-free survival (b) for all patients. Median OS was 20.0 months, and the 1- and 2-year OS rates were 71.2% and 26.3%, respectively. Median PFS was 13.0 months, and the 1- and 2-year PFS rates were 52.6% and 20.6%, respectively.
